Legal & General Group
ZVRA icon

Legal & General Group’s Zevra Therapeutics ZVRA Stock Holding History

Legal & General Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Buy
1,163,090
+65,102
+6% +$587K ﹤0.01% 1078
2025
Q4 		$9.84M Buy
1,097,988
+44,589
+4% +$422K ﹤0.01% 1180
2025
Q3 		$10M Buy
1,053,399
+117,722
+13% +$1.18M ﹤0.01% 1215
2025
Q2 		$8.24M Buy
935,677
+197,940
+27% +$1.61M ﹤0.01% 1289
2025
Q1 		$5.52M Buy
737,737
+732,436
+13,817% +$5.82M ﹤0.01% 1480
2024
Q4 		$44.2K Buy
5,301
+762
+17% +$6.5K ﹤0.01% 2803
2024
Q3 		$31.5K Buy
4,539
+688
+18% +$4.67K ﹤0.01% 2881
2024
Q2 		$18.9K Buy
3,851
+526
+16% +$2.49K ﹤0.01% 3043
2024
Q1 		$19.3K Hold
3,325
– – ﹤0.01% 2981
2023
Q4 		$21.8K Hold
3,325
– – ﹤0.01% 2998
2023
Q3 		$16K Hold
3,325
– – ﹤0.01% 3114
2023
Q2 		$17K Buy
+3,325
New +$17.9K ﹤0.01% 3181
2022
Q2 		– Sell
-2,642
Closed -$13K – 3677
2022
Q1 		$13K Hold
2,642
– – ﹤0.01% 3345
2021
Q4 		$23K Hold
2,642
– – ﹤0.01% 3236
2021
Q3 		$25K Hold
2,642
– – ﹤0.01% 3199
2021
Q2 		$34K Buy
+2,642
New +$28.4K ﹤0.01% 3093

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Legal & General Group's ZVRA Position: Q1 2026 in Review

Legal & General Group increased its Zevra Therapeutics (ZVRA) stake by 5.9% in Q1 2026, buying an estimated $587K and bringing the position to 1,163,090 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1078.

Legal & General Group first reported a position in ZVRA in Q2 2021 and has held it in 16 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Legal & General Group held 1,163,090 shares of Zevra Therapeutics worth $10.8M as of Q1 2026.
  • Legal & General Group bought 65,102 Zevra Therapeutics shares in Q1 2026, an estimated $587K.
  • Zevra Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1078 holding.
  • Legal & General Group first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.